# PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

> **NCT00908414** · PHASE1 · WITHDRAWN · sponsor: **Tibotec Pharmaceuticals, Ireland**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC589337 40 mg
- **DRUG:** TMC589337 100 mg
- **DRUG:** TMC589337 200 mg
- **DRUG:** TMC589337 400 mg
- **DRUG:** TMC589354 40 mg
- **DRUG:** TMC589354 100 mg
- **DRUG:** TMC589354 200 mg
- **DRUG:** TMC589354 400 mg
- **DRUG:** TMC589337 AA mg
- **DRUG:** TMC589354 BB mg
- **DRUG:** TMC589337 CC mg
- **DRUG:** TMC589354 DD mg
- **DRUG:** TMC589337 EE mg
- **DRUG:** TMC589354 YY mg
- **DRUG:** TMC310911 300 mg
- **DRUG:** TMC310911 600 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00908414
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-05
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** strategic decision
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908414, "PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00908414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*